Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $151.67M.
ENTERPRISE VALUE (EV)
$151.67M
ALX Oncology Holdings Inc.
Market Cap
$162.82M
Enterprise Value (EV)
$151.67M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $162.82M | $151.67M |
| Inogen, Inc. (INGN)vs › | $160.82M | $89.34M |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | $125.97M |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | $147.17M |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | $127.82M |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | $34.12M |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | $133.87M |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | $116.19M |
| Codexis, Inc. (CDXS)vs › | $149.51M | $194.93M |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | $168.38M |
Market Cap
$162.82M
Total Debt
$5.22M
Cash
$16.37M
Enterprise Value
$151.67M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
